Armata posts Q2 2026 profit on loan revaluation
Armata Pharmaceuticals reported second quarter 2026 results and provided an update on its bacteriophage pipeline.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Armata Pharmaceuticals reported second quarter 2026 results and provided an update on its bacteriophage pipeline. The company is preparing to initiate a pivotal Phase 3 superiority study of AP-SA02 for complicated Staphylococcus aureus bacteremia in the second half of 2026, following submission of the Phase 3 protocol to the FDA, completion of End-of-Phase 2 interactions, CMC progress, and FDA agreement on an Agreed Initial Pediatric Study Plan. AP-SA02 has Qualified Infectious Disease Product and Fast Track designations, and positive Phase 2a diSArm data were previously highlighted at IDWeek 2025.
For the quarter ended June 30, 2026, grant and award revenue was $2.5 million, up from $2.2 million a year earlier. Research and development expenses were $7.6 million and general and administrative expenses $5.2 million, resulting in a loss from operations of $10.3 million versus $6.8 million in 2025. Other income, net, was $84.5 million, primarily from a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by $6.6 million of interest expense. Net income was $74.1 million, or $2.02 per basic share and a $(0.27) loss per diluted share. Cash and cash equivalents were $24.0 million at June 30, 2026, up from $8.7 million at December 31, 2025, mainly reflecting a $25.0 million term loan, $2.4 million of at-the-market equity proceeds, and $1.2 million from stock option exercises, partly offset by cash used in operations.
Positive
- Net income of $74.1 million in Q2 2026 versus a prior-year loss, driven by a large non-cash gain on the Convertible Loan.
- Cash and cash equivalents rose to $24.0 million from $8.7 million at year-end 2025, supported by a $25.0 million term loan and equity proceeds.
- AP-SA02 advanced toward Phase 3, including FDA Fast Track designation, agreed pediatric study plan, and readiness for a pivotal superiority study in H2 2026.
Negative
- Loss from operations increased to $10.3 million in Q2 2026 from $6.8 million a year earlier as R&D and G&A spending grew.
- Total liabilities of $321.1 million far exceed assets of $89.9 million, resulting in a stockholders’ deficit of $231.2 million.
- Interest expense rose to $6.6 million for the quarter, reflecting a higher debt load including term debt and the Convertible Loan.
8-K Event Classification
Key Figures
Key Terms
Convertible Loan financial
Qualified Infectious Disease Product (QIDP) regulatory
Fast Track designation regulatory
Biologics License Application regulatory
at-the-market offering program financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Armata Pharmaceuticals (ARMP) perform financially in Q2 2026?
What were Armata Pharmaceuticals’ (ARMP) revenues and operating loss in Q2 2026?
What is Armata Pharmaceuticals’ (ARMP) cash position as of June 30, 2026?
What progress did Armata Pharmaceuticals (ARMP) report on AP-SA02?
What is the debt and liability profile of Armata Pharmaceuticals (ARMP)?
What drove the large other income for Armata Pharmaceuticals (ARMP) in Q2 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
(
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | | Trading Symbol(s) | | Name of Each Exchange on Which Registered |
Item 2.02Results of Operations and Financial Condition.
On August 12, 2026, the Company announced its financial results for the three and six months ended June 30, 2026, in the press release furnished hereto as Exhibit 99.1.
The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit | | Description |
99.1 | Press Release, dated August 12, 2026. | |
104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 12, 2026 | Armata Pharmaceuticals, Inc. | |
By: | /s/ David House | |
Name: | David House | |
Title: | Chief Financial Officer (Principal Financial Officer) | |
Exhibit 99.1
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.
“We continue to finalize activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “We recently submitted the Phase 3 protocol to the FDA, responded to the Agency's End-of-Phase 2 meeting minutes, and continued to advance manufacturing, each of these key milestones supporting study initiation. Complicated S. aureus bacteremia is associated with substantial morbidity and mortality, underscoring the need for new treatments. We believe AP-SA02, a novel intravenous phage therapeutic, has the potential to be a valuable and differentiated approach for patients in need.”
“We also achieved several additional important milestones for AP-SA02, including FDA agreement on our Agreed Initial Pediatric Study Plan, granting of Fast Track designation by the FDA, and receipt of additional non-dilutive funding from our partners at the U.S. Department of War. We were pleased to promote David House to Chief Financial Officer, ensuring we have the financial leadership in place to execute our late-stage clinical development goals,” concluded Dr. Birx.
Second Quarter 2026 and Recent Developments:
Clinical, Regulatory, Manufacturing, and Operational Progress
Armata has made significant progress across clinical, regulatory, manufacturing, and operational fronts supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, toward a Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus (“MRSA”). Collectively, these milestones support the planned pivotal Phase 3 superiority study, expected to initiate in the second half of 2026, and designed to support a future Biologics License Application (“BLA”) for AP-SA02.
Clinical
| ● | Submitted the complete Phase 3 superiority protocol to the U.S. Food and Drug Administration (the “FDA”), incorporating all comments received in the End-of-Phase 2 (“EOP2”) meeting written response. |
Chemistry, Manufacturing, and Controls (“CMC”)
| ● | Submitted responses to all FDA comments raised in the EOP2 meeting written response. |
| ● | Completed the validation and certification of essential lot release assays for drug substance and drug product. |
| ● | Completed four engineering runs of AP-SA02 at the Company’s in-house current Good Manufacturing Practices (“cGMP”) manufacturing facility in Los Angeles, CA. Production of clinical trial material to support the planned Phase 3 clinical study is the next planned manufacturing step. |
| ● | Simplified drug product for enhanced ease of use at the bedside and potential future U.S. Department of War (“DoW”) forward deployment. |
Key Regulatory Milestones
| ● | FDA granted Fast Track designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA, advancing AP-SA02 on a faster path to potential approval and patient access. |
| o | Intended to facilitate the development and expedite the review of investigational therapies that treat serious conditions and fill an unmet medical need. |
| o | Provides for more frequent interactions with the FDA regarding all aspects of a drug’s clinical development program, supporting a more efficient path to registration. |
| o | Allows for rolling review of a BLA, meaning completed sections may be submitted and reviewed on an ongoing basis rather than waiting for the full application. |
| o | Fast Track-designated programs may also be eligible for Accelerated Approval and Priority Review if supported by clinical data at the time of BLA submission, further supporting a faster path to potential approval and patient access. |
| ● | Received agreement from the FDA on an Agreed Initial Pediatric Study Plan (“Agreed iPSP”) which establishes the agreed regulatory framework for the future evaluation of AP-SA02 for the adjunct treatment of SAB in pediatric patients. |
| o | The Agreed iPSP outlines a proposed pediatric development program targeting patients up to 17 years of age with complicated S. aureus bacteremia (“SAB”), the same indication Armata is pursuing in adults, with pediatric studies deferred until safety and efficacy data are generated in adults in the planned Phase 3 program. |
| o | This strategy establishes a pathway for potential future expansion of AP-SA02 into the pediatric population while prioritizing patient safety and efficient clinical development. |
Funding
| ● | Continued support from the DoW: Received $2.5 million of additional non-dilutive funding from the DoW i to support AP-SA02. These funds are a continuation of the previously announced award from the DoW, bringing the total funding received to date under this award to $28.7 million, and are intended to support activities related to the Company’s continued preparation and readiness for its planned Phase 3 clinical study. |
| ● | Separate from the existing or any potential new DoW award, the Company continues to pursue and evaluate other funding pathways to support the execution of the planned Phase 3 clinical study. |
Executive Leadership and Corporate Governance
| ● | Promoted David House to Chief Financial Officer. Mr. House has served as the Company’s Senior Vice President, Finance and Principal Financial Officer since August 2024. |
| ● | Appointed accomplished healthcare executive Daniel B. Gilmer, Ph.D. to the Board of Directors bringing experience in commercialization (Pfizer, Inc.), management consulting (McKinsey & Co.), and research (Rockefeller University, National Institutes of Health). |
Publications
| ● | Further advanced bacteriophage science through the publication of a paper, titled, “Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection" in Communications Biology, a peer-reviewed journal from Nature Portfolio. The paper describes the structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02. |
Second Quarter 2026 Financial Results
Grant and Award Revenue. The Company recognized grant and award revenue of $2.5 million for the three months ended June 30, 2026, as compared to $2.2 million in the comparable period in 2025. This represents the Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of SAB.
Research and Development. Research and development expenses for the three months ended June 30, 2026 were approximately $7.6 million, compared to approximately $6.4 million for the comparable period in 2025. The increase primarily reflected higher non-cash stock-based compensation primarily related to option grants issued after the second quarter of 2025.
General and Administrative. General and administrative expenses for the three months ended June 30, 2026 were approximately $5.2 million, compared to approximately $2.6 million for the comparable period in 2025. The increase primarily reflected higher non-cash stock-based compensation primarily related to option grants issued after the second quarter of 2025.
Loss from Operations. Loss from operations for the three months ended June 30, 2026 was approximately $10.3 million, compared to a loss from operations of approximately $6.8 million for the comparable period in 2025. The increase primarily reflected the higher research and development and general and administrative expenses described above, partially offset by higher grant and award revenue.
Other Income (Expense). Other income, net, for the three months ended June 30, 2026 was approximately $84.5 million, compared with other expense, net, of approximately $9.5 million for the comparable period in 2025. Other income in the second quarter of 2026 primarily reflected a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by $6.6 million of interest expense.
Net Income (Loss). The net income for the second quarter of 2026 was $74.1 million, or $2.02 earnings per share on a basic basis and a ($0.27) loss per share on a diluted basis, as compared to a net loss of ($16.3) million, or ($0.45) loss per share on a basic and diluted basis, for the comparable period in 2025.
Cash and Cash Equivalents. As of June 30, 2026, Armata held approximately $24.0 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025. The increase primarily reflected the $25.0 million term loan funded in May 2026, approximately $2.4 million of net proceeds under the Company’s at-the-market offering program and approximately $1.2 million of proceeds from stock option exercises, partially offset by cash used in operations.
As of August 06, 2026, 37,181,979 common shares were outstanding.
About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking
statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
Armata Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| | June 30, 2026 | | December 31, 2025 | | ||
Assets | | | | | | | |
Current assets | | | | | | | |
Cash and cash equivalents | | $ | 23,952 | | $ | 8,688 | |
Prepaid expenses and other current assets | |
| 673 | |
| 1,508 | |
Other receivables | | | 2,532 | | | 472 | |
Total current assets | |
| 27,157 | |
| 10,668 | |
Property and equipment, net | |
| 11,230 | |
| 12,194 | |
Operating lease right-of-use asset | |
| 32,884 | |
| 33,911 | |
Intangible assets, net | | | 13,746 | | | 13,746 | |
Other long-term assets | |
| 4,933 | |
| 6,363 | |
Total assets | | $ | 89,950 | | $ | 76,882 | |
| | | | | | | |
Liabilities and stockholders’ deficit | |
| | |
| | |
Accounts payable, accrued and other current liabilities | | $ | 8,715 | | $ | 8,947 | |
Convertible Loan, current | | | 163,904 | | | — | |
Term debt, current | | | 77,580 | | | — | |
Total current liabilities | | 250,199 | | 8,947 | | ||
Convertible Loan, non-current | | | — | | | 153,860 | |
Term debt, non-current | | | 42,024 | | | 103,061 | |
Operating lease liabilities, net of current portion | | | 25,823 | | | 26,533 | |
Deferred tax liability | | | 3,077 | | | 3,077 | |
Total liabilities | |
| 321,123 | |
| 295,478 | |
Total stockholders’ deficit | |
| (231,173) | |
| (218,596) | |
Total liabilities and stockholders’ deficit | | $ | 89,950 | | $ | 76,882 | |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
| 2026 | | 2025 | | 2026 | | 2025 | ||||
Grant and award revenue | $ | 2,510 | | $ | 2,169 | | $ | 3,299 | | $ | 2,660 |
Operating expenses | | | | | | | | | | | |
Research and development |
| 7,586 | | | 6,394 | |
| 13,697 | | | 11,823 |
General and administrative |
| 5,236 | | | 2,619 | |
| 8,699 | | | 5,872 |
Total operating expenses | | 12,822 | | | 9,013 | | | 22,396 | | | 17,695 |
Operating loss |
| (10,312) | |
| (6,844) | |
| (19,097) | |
| (15,035) |
Other income (expense) |
| | |
| | |
| | |
| |
Interest income | | 69 | | | 108 | | | 129 | | | 167 |
Interest expense | | (6,634) | | | (3,808) | | | (12,193) | | | (7,410) |
Change in fair value of the Convertible Loan | | 91,018 | | | (5,751) | | | (10,044) | | | (548) |
Total other income (expense), net |
| 84,453 | |
| (9,451) | |
| (22,108) | |
| (7,791) |
Net income (loss) | $ | 74,141 | | $ | (16,295) | | $ | (41,205) | | $ | (22,826) |
Per share information: | | | | | | | | | | | |
Net income (loss) per share, basic | $ | 2.02 | | $ | (0.45) | | $ | (1.12) | | $ | (0.63) |
Weighted average shares outstanding, basic | | 36,747,840 | | | 36,193,479 | | | 36,639,663 | | | 36,189,165 |
Net loss per share, diluted | $ | (0.27) | | $ | (0.45) | | $ | (1.12) | | $ | (0.63) |
Weighted average shares outstanding, diluted | | 62,041,700 | | | 36,193,479 | | | 36,639,663 | | | 36,189,165 |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| | Six Months Ended June 30, | ||||
| | 2026 | | 2025 | ||
Operating activities: | | | | | | |
Net loss | | $ | (41,205) | | $ | (22,826) |
Adjustments required to reconcile net loss to net cash used in operating activities: | | | | | | |
Depreciation expense | |
| 1,048 | |
| 743 |
Stock-based compensation expense | | | 4,466 | | | 1,356 |
Change in fair value of the Convertible Loan | | | 10,044 | | | 548 |
Non-cash interest expense | | | 12,183 | | | 7,398 |
Change in right-of-use asset | | | 1,027 | | | 1,183 |
Changes in operating assets and liabilities: | |
| (2,011) | |
| (3,193) |
Net cash used in operating activities | |
| (14,448) | |
| (14,791) |
Investing activities: | |
| | |
| |
Purchases of property and equipment | | | (80) | | | (248) |
Net cash used in investing activities | |
| (80) | | | (248) |
Financing activities: | |
| | |
| |
Proceeds from issuance of term debt, net of issuance costs | | | 25,000 | | | 10,000 |
Proceeds from issuance of common stock under ATM, net | | | 2,373 | | | — |
Payments for taxes related to net share settlement of equity awards | | | (63) | | | (14) |
Proceeds from exercise of stock options | | | 1,212 | | | — |
Net cash provided by financing activities | |
| 28,522 | |
| 9,986 |
Net change in cash, cash equivalents and restricted cash | |
| 13,994 | |
| (5,053) |
Cash, cash equivalents and restricted cash, beginning of period | |
| 14,078 | |
| 14,771 |
Cash, cash equivalents and restricted cash, end of period | | $ | 28,072 | | $ | 9,718 |
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | | Six Months Ended June 30, | ||||
| | 2026 | | 2025 | ||
Cash and cash equivalents | | $ | 23,952 | | $ | 4,328 |
Restricted cash | | | 4,120 | | | 5,390 |
Cash, cash equivalents and restricted cash | | $ | 28,072 | | $ | 9,718 |
i Department of War (DoW) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.